We have a team of experts with incredible knowledge and experience in a variety of backgrounds.
Board and Executive Management
XPhyto’s board and executive management bring significant expertise in science, therapeutics, business development and growth. Combine the collective skills of the team with an entrepreneurial eye for opportunity and you can see why XPhyto is poised to be a disrupter in the pharmaceutical industry.
Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles.
Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. Mr. Rogers has held several board and executive management positions with junior exchange listed issuers. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. He is a member in good standing of the Law Society of British Columbia.
Mr. Ross, CPA, CGA is a professional accountant with broad financial experience across numerous industries. He has provided financial accounting, strategic analysis, and consulting services to public and private companies and facilitated numerous transactions involving debt and equity financings, mergers and acquisitions, corporate re-organizations and divestitures. Mr. Ross is the principal of Modum Corporate Services Inc, a firm focused on providing companies with consulting and other accounting services. Mr. Ross holds a bachelor’s degree in Commerce (Accounting) and is a member in good standing of the Chartered Professional Accountants Association of British Columbia.
Mr. Probst is an experienced management consultant specialized in investment consulting and capitalization.
He’s an expert in mergers and acquisitions, corporate re-organizations, and divestitures and has adroitly brought multiple startups to success. Owing to his superior negotiating skills, he has a proven track record in strategic analysis, which resulted in highly targeted organizational restructuring.
Prof. Dr. Raimar Löbenberg
Dr. Löbenberg holds a bachelor’s of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Löbenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis or leishmanasis. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.
Dr. Löbenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.
Mr. Damouni is an entrepreneur and financier with over 18 years of
experience in investment banking and capital markets including more than 10
years as a director or an officer of a number of private and public
companies listed on the TSX, the TSXV and LSE.
Throughout his career, Mr. Damouni has taken a lead role in equity and debt financings. His expertise on financing, restructuring, strategy
development and execution, mergers and acquisitions has been instrumental in creating significant value for shareholders in the consumer, natural resources, technology and life sciences sectors.
Prof. Dr. Thomas Beckert
Prof. Dr. Beckert is the founder, managing director, and qualified person of Vektor Pharma TF GmbH, Uttenweiler, Germany. His expertise includes formulation and machine development for transdermal therapeutic systems and ODFs, narcotic drugs, cannabis, and herbal extracts in addition to global auditing of pharmaceutical and nutraceutical manufacturers (GACP, API, solids, sterile dosage forms, transport, analytical labs, microbiological labs, and pharmacovigilance). Prof. Dr. Beckert holds a Bachelor of Science degree in Pharmacy from the University of Freiburg, Freiburg im Breisgau, Germany, and a Ph.D. in Pharmacy and Economics from the University of Tübingen, Tübingen, Germany. He is currently a professor of Pharmaceutical Process Technologies, University of Applied Sciences, Albstadt-Sigmaringen.
Mr. Thoresen is an experienced leader with an impressive track record in a wide range of executive management roles in the pharmaceutical industry. He has 25 years’ experience including executive roles with major international European and Asian-based pharmaceutical companies and has more recently led a number of successful ventures in the pharmaceutical manufacturing, nutraceutical and other industry sectors. From 2003 to 2014, Mr. Thoresen was the managing director of Nycomed Pharma AS acquired by Takeda Pharmaceutical Company Limited in 2011 as part of an acquisition transaction with a total value of approximately USD $14B.
Mr. Thoresen holds a law degree from the top-ranked University of Oslo and core competencies in strategy and organizational development, operational execution, and industry and government relations. He is an experienced chairman and board member of numerous European industry associations and companies and is the co-founder and current chairman of Curida AS, a Norwegian-based contract development manufacturing organization focused on liquid pharmaceutical production.
To support XPhyto’s growth and expansion, we work with a team of advisors made up of leaders in their field who are passionate about XPhyto’s future and committed to our success.
For over 20 years, Adam has held numerous C-Level transformation and revenue growth leadership roles at multiple banks and technology firms. He is a board advisor to companies in FinTech, BioTech, Consumer Packaged Goods and AI and runs multiple Venture Capital and high yield growth funds. He specializes in revenue growth and M&A transaction advisory.
Adam’s primary experience has been in developing client-focused offerings rooted in technology. He has developed highly innovative front and back office solutions leveraging modern data and digital tools, processes partnerships and methodologies to push the envelope to challenge the status-quo.
Mr. Kretzer is an experienced pharmaceutical entrepreneur.
His experience includes management in pharmaceutical wholesale and medical devices. He is QA Officer according to §52a AMG (German Medicines Act) and Safety Officer for Medical Devices according to §30 of the German Medical Devices Act.
During his career, Mr. Kretzer has held many leadership roles in pharmaceutical sales and marketing, been responsible for study design and implementation according to GCP, built and managed sales teams in Europe, and established foreign subsidiaries in Europe and Asia.
Mr. Buchberger is an experienced leader in the medical and diagnostic products industry with an impressive track record.
For almost a decade, Mr. Buchberger was CEO and member of the Global Management Board of a medical and diagnostics product manufacturer with annual revenues of over €600 million.
He has many years of experience in international business development, sales, marketing, and product management and has successfully developed and managed business strategies and internationalization in Europe, North and South America, Middle East and Asia. Mr. Buchberger has been a key player in a wide range of successful global medical and diagnostic product launches.
Mr. Zdarek has extensive experience in the pharmaceutical industry.
In addition to a wide range of qualifications in drug safety and quality management under German drug law, Mr. Zdarek brings several decades of experience in the international pharmaceutical industry in the areas of strategic and operational management, business development, marketing and sales.
He also brings tremendous value to the team through his expertise and know-how of international regulatory processes’ successful realizations.
Prof. Dr. Wolfgang Eisenreich
Prof. Dr. Eisenreich leads a research group at the Department of Chemistry, Technical University of Munich and the Central NMR Analytics Facility at Garching. He has over 20 years of experience in the study of metabolic pathways and signaling cascades as they relate to pathogen and host cell interactions. Prof. Dr. Eisenreich’s most recent work has focused on analysis and delineation of intracellular pathogenic bacteria and host cell interactions using innovative stable isotope labelling and profiling methodologies (NMR- and MS-based metabolomics). His technology driven analysis is a powerful tool in the study of pathogen and host cell interactions with a focus on host cell response. Prof Dr. Eisenreich’s work on metabolic adaptation between intracellular pathogens and their host cells was awarded the Max-von-Pettenkofer Prize in 2015. He and his team are well suited for the molecular analysis of coronavirus infections and related drug target identification and validation.
Mr. Hughes was Chairman of a publicly listed cannabis company with operations in the most competitive cannabis market in the world, California. He raised C$27M, took the company public and delivered the construction of a 35,000 sqft premium indoor facility to production. He is an integrated marketing communications and innovations professional of 15+ years and has held board level positions for multiple companies and has success and experience in venture capital services and the commercialization of private and public companies across the globe: North America, Australia, and the Asia Pacific Region.
Dr. Allen Benson
Dr. Allen Benson, LLD is a member of the Beaver Lake First Nation. His life experience has fostered the development of strong family and community values: sharing, generosity and compassion for others which he has transformed into innovative service delivery, community-based action and a strong vision for the future of Aboriginal people. Mr. Benson has dedicated his life to advocating for the poor and disenfranchised and the actualization of healthy Aboriginal individuals, families and communities, both in Canada and internationally.
As the Chief Executive officer of Native Counselling Services of Alberta (NCSA), an agency that he has worked with for over 30 years, he has led NCSA in the development of many cutting edge programs for Aboriginal people, particularly in the areas of restorative and social justice, Aboriginal correctional services, health, housing, gang recruitment prevention/intervention and homelessness. He has also advanced the cause of Aboriginal control of community-based research and applied Aboriginal knowledge to current issues facing Aboriginal people.
Internationally, he works to achieve community-capacity building processes and structures to help Indigenous peoples to articulate and advance their visions for the future. While much of his work has focused on Aboriginal people, he also works tirelessly to use his experience and knowledge to develop the complementary partnerships that will create substantive change in both the Aboriginal and non-Aboriginal community. His accomplishments have been marked in such past rewards as the Alberta Centennial Medal, the Paul Harris Fellowship, the Edmonton and International Rotary Integrity Award, the Alberta Aboriginal Role Model Award in Justice, the DreamSpeakers Walk of Fame and an Honorary Doctorate from the University of Alberta.
“We have ambitious milestones for XPhyto’s future, and I am confident our team will execute.”
– Hugh Rogers, CEO